Communiqués Plus Therapeutics, Inc.

Actions

PSTV

US72941H8060

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 08/07/2026			Varia. 5j.	Varia. 1 janv.
3,820 ^USD	-2,55%		-8,17%	-70,17%

30/06	Transcript : Plus Therapeutics, Inc. - Special Call
30/06	Plus Therapeutics progresse dans les essais cliniques et la production du REYOBIQ	CI

Communiqués

30/06	Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding	AQ
26/06	Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide Cerebrospinal Fluid Assay for Metastatic CNS Cancer	AQ
25/06	Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer	AQ
23/06	Plus Therapeutics to Provide Business Update Call on June 30, 2026	AQ
05/06	Plus Therapeutics Announces CAP Accreditation of CNSide Diagnostics Clinical Laboratory	AQ
04/06	Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory	AQ
26/05	Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases	AQ
19/05	Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology	AQ
15/05	Plus: Q1 Earnings Snapshot	AQ
15/05	Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout	AQ
08/05	Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases	AQ
07/05	Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic	AQ
28/04	Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer	AQ
23/04	Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™	AQ
22/04	Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	AQ
21/04	Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement	AQ
15/04	Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution	AQ
09/04	Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline	AQ
08/04	Plus Therapeutics Receives AMA PLA Code for CNSide CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption	AQ
08/04	Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas	AQ
07/04	Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption	AQ
02/04	Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives	AQ
31/03	Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	AQ
31/03	Plus Therapeutics Announces Reverse Stock Split	AQ
26/03	Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors	AQ